Vineet Laboratories Q2 Results 2026: PAT ₹0 Cr (−70% YoY)
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹14Cr
- −18.6% YoY
- +36.5% QoQ
- Net profit
- ₹0Cr
- −70% YoY
- −92.1% QoQ
- Margin
- 16.4%
- −1.9 pp YoY
- −5.3 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Vineet Laboratories Ltd Q2 FY27 key numbers
- Revenue
- Revenue / Sales for quarter ended September 30, 2026: INR 1,418.30 lakh.
As stated in Vineet Laboratories Ltd's Q2 FY27 results statement · published 12 Nov 2026. Reported figures, not investment advice.
Based on Vineet Laboratories Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue / Sales for quarter ended September 30, 2026: INR 1,418.30 lakh. Quarterly EBITDA: ₹283.0 lakh, up 115% year-on-year (YoY).
From Vineet Laboratories Ltd's Q2 FY27 earnings-call transcript · updated 12 Nov 2026.
How did Vineet Laboratories' revenue grow in the September 2026 quarter?
- Revenue / Sales for quarter ended September 30, 2026: INR 1,418.30 lakh
- Revenue / Sales for quarter ended September 30, 2025: INR 1,741.95 lakh
- Year-on-year change: Decrease of approximately INR 323.65 lakh or about 18.58% decline
- Total income for the quarter ended September 30, 2026: INR 1,420.15 lakh
What happened to Vineet Laboratories' margins in Q2 FY27?
Quarterly EBITDA: ₹283.0 lakh, up 115% year-on-year (YoY)
Locked: what Vineet Laboratories Ltd said on margins
Also locked on this page: fundraising, order book
Free account, 30 seconds. No card needed.
What capex is Vineet Laboratories planning?
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Vineet Laboratories raising money or cutting debt?
The Statement of Cash Flows (Page 5) indicates fundraising activities including:
Locked: what Vineet Laboratories Ltd said on fundraising
Also locked on this page: margins, order book
Free account, 30 seconds. No card needed.
How big is Vineet Laboratories' order book?
See what Vineet Laboratories Ltd said on order book & pipeline — free account, 30 seconds.
Vineet Laboratories Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the table below.
Vineet Laboratories Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 14 | 17 | -18.6% | 10 | +36.5% |
| Operating profit (EBITDA) | 2 | 3 | -27% | 2 | +3.1% |
| Operating margin | 16.4% | 18.3% | -1.9 pp | 21.7% | -5.3 pp |
| Profit before tax | 1 | 0 | +275.7% | 1 | +75.9% |
| Net profit (PAT) | 0 | 0 | -70% | 2 | -92.1% |
| EPS (₹) | 0.06 | 0.43 | -86% | 0.73 | -91.8% |
Source: Vineet Laboratories Ltd's results filing to NSE (standalone), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹10 Cr, net profit ₹2 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Innova Captab (Q2 FY27)
Revenue from Operations for Q2 FY27 was ₹496.3 crore, a 30.5% year-on-year (YoY) increase from ₹380.4 crore in Q2 FY26 (Page 11). Key investor presentation take
- Viyash Scientific (Q2 FY27)
Q2 FY27 revenue from operations: ₹9,879 million, up 16.2% YoY (Page 8) . Key investor presentation takeaways from Viyash Scientific Ltd's Q2 FY27 investor prese
- Natco Pharma (Q2 FY27)
EBITDA for Q2 FY27: INR 3,100 Mn, down from INR 6,792 Mn in Q2 FY26 (54.4% decline) . Key investor presentation takeaways from Natco Pharma Ltd's Q2 FY27 invest
- Balaxi Pharma (Q2 FY27)
34.1% increase (from Rs. Key results statement takeaways from Balaxi Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Vineet Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Vineet Laboratories Ltd Q2 FY27 results?
Revenue / Sales for quarter ended September 30, 2026: INR 1,418.30 lakh. Quarterly EBITDA: ₹283.0 lakh, up 115% year-on-year (YoY).
What is Vineet Laboratories Ltd share price analysis?
Vineet Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 20.9 with a market cap of ₹73 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Vineet Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.